Group Marinoni, Perren, Sadowski

Group Marinoni, Perren, Sadowski


SNF 320030_214902 (2023-2027) (Ilaria Marinoni): "Dissecting the role of tumor cell heterogeneity in Pancreatic Neuroendocrine Tumors progression"

Swiss 3RCC - Knowledge Transfer KT-2022-002 (2023)  (Martin Sadowski PI): Modelling acquired drug resistance by high content imaging and multivariate analysis of patient-derived organoids¨

Bern Center for Precision Medicine (2022-2024) (Ilaria Marinoni): "Establishment of an in vitro and in vivo pipeline for precision medicine in Neuroendocrine tumors."

KFS-5539-02-2022 (2022-2025) (Martin Sadowski): "Targeting drug-tolerant persister cells - an early offensive against acquired drug resistance in pancreatic neuroendocrine tumours"

SNF 310030_188639 (2020-2024) (Aurel Perren): "Metabolic changes in early and late progression steps of pancreatic neuroendocrine tumors"

ENETs CO-Synergy Award (2019-2022) (Ilaria Marinoni): "Studying poor responders to Temozolomide (TMZ) in Pancreatic Neuroendocrine Tumours (Pan-NETs). Unravelling mechanisms of primary resistance."

KLS-4227-08-2017 (Aurel Perren PI and Ilaria Marinoni Co-PI) (2018-2022)  "Precision medicine approach for novel epigenetic treatment for pancreatic neuroendocrine tumors (PanNET)"

Berner Krebsliga (Matthias Dettmer)   (2017 – 2022)  "Tumor heterogeneity and epigenetics in high-risk thyroid carcinomas"